Skip to content

Transcranial Direct Current Stimulation in the Treatment of Primary Progressive Aphasia

Logopenic Progressive Aphasia | Primary Progressive Aphasia | Non-Fluent Primary Progressive Aphasia

While many have strongly suggested that transcranial direct current stimulation (tDCS) may represent a beneficial intervention for patients with primary progressive aphasia (PPA), this promising technology has not yet been applied widely in clinical settings. This treatment gap is underscored by the absence of any neurally-focused standard-of-care treatments to mitigate the devastating impact of aphasia on patients' family, work, and social lives. Given that tDCS is inexpensive, easy to use (it is potentially amenable to home use by patients and caregivers), minimally invasive, and safe there is great promise to advance this intervention toward clinical use. The principal reason that tDCS has not found wide clinical application yet is that its efficacy has not been tested in large, multi-center, clinical trials. In this study, scientists in the three sites that have conducted tDCS clinical trials in North America-Johns Hopkins University and the University of Pennsylvania in the US, and the University of Toronto in Canada, will collaborate to conduct a multi-site, Phase II clinical trial of tDCS a population in dire need of better treatments.

null

Conditions de participation

  • Sexe:

    ALL

  • Âges admissibles:

    50 to 80

Critères de participation

Inclusion Criteria:

* Presence of aphasia attributable to non-fluent PPA or logopenic PPA
* High school education (or more)
* Between the ages of 50 and 80
* Must be able to understand the nature of the study and give informed consent

Exclusion Criteria:

* Cognitive impairment of sufficient severity to preclude giving informed consent (Mini Mental State Examination \[MMSE\] less than 15 or Montreal Cognitive Assessment \[MOCA\] less than 10; Frontotemporal Dementia - Modified Clinical Dementia Rating \[FTD-CDR\] Scale score =3)
* Any unrelated neurologic of physical condition that impairs communication ability
* History of unrelated neurological conditions, including but not limited to traumatic brain injury (TBI), stroke, or small vessel disease, that has resulted in a neurologic deficit
* Any additional neurological condition that would likely reduce the safety of study participation, including central nervous system (CNS) vasculitis, intracranial tumor, intracranial aneurysm, multiple sclerosis or arteriovenous malformations
* A medically unstable cardiopulmonary or metabolic disorder
* Individuals with pacemakers or implantable cardiac defibrillators
* Terminal illness associated with survival of less than 12 months
* Major active psychiatric illness that may interfere with required study procedures or treatments, as determined by enrolling physician
* Current abuse of alcohol or drugs, prescription or otherwise
* Participant in another drug, device or biologics trial within 30 days prior to enrollment
* Nursing a child, pregnant or intent to become pregnant during the study
* Left-handedness

Exclusion for tDCS, specifically:

* History of spontaneous or partial complex seizures or unexplained loss of consciousness within 6 months of enrollment
* Subjects with metallic objects in the face or head other than dental apparatus, such as braces, fillings or implants
* Subjects with previous craniotomy or any breach in the skull

Exclusion for MRI, specifically:

* Presence of any of the following devices: cardiac pacemaker, other pacemakers (for carotid sinus, insulin pumps, nerve stimulators, lead wires or similar wires), optic implant, implanted cardiac defibrillator, aneurysm clip, any electronically/magnetically/mechanically activated implant, ferromagnetic implants (coils, filters, stents; metal sutures or staples)
* Presence of any of the following: pregnancy, claustrophobic, metal in eye or orbit, tattooed eyeliner

Lieu de l'étude

Baycrest Centre for Geriatric Care
Baycrest Centre for Geriatric Care
Toronto, Ontario
Canada

Contactez l'équipe d'étude

Primary Contact

Howard Chertkow, PhD

[email protected]
416-785-2500
Étude parrainée par
Johns Hopkins University
Participants recherchés
Plus d'informations
ID de l'étude: NCT05386394